Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Renal Disease
- Infectious Disease
- Forensic and Legal Medicine
- Chronic Disease
- Hepatitis
- Respiratory Medicine
- Anatomy
- Dentistry and Oral Biology
Abstract
Citation: Ann Clin Case Rep. 2017;2(1):1382.DOI: 10.25107/2474-1655.1382
Anti-CTLA-4 Monoclonal Antibodies Induced Hypophysitis: Case Report and Literature Review
Jaafar Jaafar and Jacques Philippe
Division of Endocrinology and Diabetology, Geneva University Hospitals and Faculty of Medicine, Switzerland
*Correspondance to: Jaafar Jaafar
PDF Full Text Case Report | Open Access
Abstract:
Treatment with Anti-CTLA-4 Monoclonal Antibodies (mAb) has become a common choice in advanced melanoma and is under evaluation for many other types of cancer. These antibodies inhibit the interaction between CTLA-4 (Cytotoxic T Lymphocyte-Associated Antigen 4) receptors on the T cell surface and the antigen presenting cell surface molecules B7, leading to the activation or enhancement of T cell immune responses. The oncologic beneficial effects of Anti-CTLA-4 mAb are marred by many immune related adverse effects, including Ipilimumab-Induced Hypophysitis (IIH). We, herein, report an illustrative case with a literature review. Based on this research, the incidence of IIH was between 1.75% and 13%. Presenting symptoms were predominantly headache and fatigue. Pituitary enlargement was the main radiologic sign on MRI. The thyrotrophic and adrenocorticotropic axes were the most commonly affected followed by gonadotropic, somatotropic and lactotropic axes, respectively. Time to hypophysitis onset varied between 5 and 40 weeks after starting ipilimumab and treatment withdrawal due to hypophysitis was largely variable. Finally, thyrotropin and gonadotropin axes recovered more frequently than other anterior pituitary axes.
Keywords:
Cite the Article:
Jaafar J, Philippe J. Anti-CTLA-4 Monoclonal Antibodies Induced Hypophysitis: Case Report and Literature Review. Ann Clin Case Rep. 2017; 2: 1382.